Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Prognostic factors]

M Paesmans1

  • 1Unité de Biostatistique, Institut Jules Bordet, Bruxelles.

Revue Des Maladies Respiratoires
|August 5, 1998
PubMed
Summary
This summary is machine-generated.

Identifying prognostic factors for stage III small cell lung cancer (SCLC) aids treatment decisions. Classical factors like performance status and TNM substage are key, but further validation is needed for improved survival prediction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based study.

ESMO open·2026
Same author

Retrospective study evaluating dental side effects of radiotherapy in patients treated for head and neck cancer.

Journal of stomatology, oral and maxillofacial surgery·2024
Same author

Risk factors for imminent fractures: a substudy of the FRISBEE cohort.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

Discriminating value of HR-pQCT for fractures in women with similar FRAX scores: A substudy of the FRISBEE cohort.

Bone·2020
Same author

Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

What is the validity of self-reported fractures?

Bone reports·2020
Same journal

[French version of the guidelines for connective tissue disease-associated ILD].

Revue des maladies respiratoires·2026
Same journal

[Pulmonary expression of an asymptomatic lysosomal storage disorder].

Revue des maladies respiratoires·2026
Same journal

[Factors associated with FEV1 evolution in cystic fibrosis patients treated by CFTR modulator tritherapy].

Revue des maladies respiratoires·2026
Same journal

[Subacute pulmonary coccidioidomycosis: A differential diagnosis of lung cancer].

Revue des maladies respiratoires·2026
Same journal

[Relevance of the ACT score in severe asthma with obesity: A pilot study].

Revue des maladies respiratoires·2026
Same journal

[Automated analysis of mandibular movements for the screening of obstructive sleep apnea].

Revue des maladies respiratoires·2026
See all related articles

Area of Science:

  • Oncology
  • Pulmonology
  • Clinical Research

Background:

  • Pretherapeutic factors guide individual patient treatment and inform clinical study design.
  • Accurate prognostic factors are crucial for managing stage III small cell lung cancer (SCLC).

Purpose of the Study:

  • To review classical prognostic factors for survival in stage III SCLC patients.
  • To identify factors usable in daily clinical practice for SCLC prognosis.

Main Methods:

  • Literature review of "classical" prognostic factors for stage III SCLC.
  • Analysis of factors including operability, TNM substage, histology, sex, age, performance status, and serum markers.

Main Results:

  • Operability status correlates with TNM substage (IIIA/IIIB).

Related Experiment Videos

  • For operable patients, histology, male sex, age >65, low performance status, and N2 disease suggest unfavorable prognosis.
  • For inoperable patients, good performance index is a favorable prognostic feature.
  • TNM substage, sex, weight loss, and LDH levels may improve prognostic models.

    • Conclusions:

    • Classical prognostic factors offer initial guidance for stage III SCLC management.
    • Further prospective, multivariate studies are needed to validate prognostic variables and indexes for improved prediction accuracy.